Author:
S .Muthukumar,C .Sankar,K .Swetha,R. Pradeepa,B .Muneeswaran,M .Noori Irfna Parvin,J Sangeetha.
Abstract
In the modern times, vesicular system is a well-known carrier for delivery of drugs. They can carry both lipophilic and hydrophilic drugs. Proniosomes are a vital member of novel drug delivery carriers. The present study was aimed to develop and prepare Metronidazole Benzoate loaded proniosomes with different ratios of cholesterol and non-ionic surfactants to prolong the drug release on topical administration. By slurry method, about fourteen formulations were prepared and evaluated for angle of repose, drug content, particle size, hydration rate, encapsulation efficiency, in-vitro release studies & ex-vivo drug permeation studies. The optimized formulation of proniosomes was developed into transdermal patch and was subjected to various evaluation studies. The in-vitro kinetic and diffusion study of the patch showed a release of 80.71% over 12hrs and fitted into zero order and non-fickian diffusion mechanism. It was summed up, that the formulation F12 containing surfactant: cholesterol as 1:1 was the best formulation. Incorporation into proniosomes can lead to reduced dose, improved bioavailability and prolonged release. Further formulating in form of transdermal patch allows controlled release of the drug. UV spectrophotometric method was developed for determining Metronidazole benzoate in 5% ethanol at 309nm. A regression coefficient value of 0.9977 was noticed. The SEM image as well as the FT-IR spectrum of the optimized formulation was taken to support the same. Hence, we conclude that the proniosomal formulation is a vital candidate for transdermal delivery of metronidazole benzoate in the treatment of various systemic as well as topical bacterial infections
Publisher
International Journal of Pharma and Bio Sciences
Subject
Cell Biology,Molecular Biology,Biochemistry,Biotechnology
Reference28 articles.
1. 1. Solanki AB, Parikh JR, Parikh RH. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level Box-Behnken design. AAPS PharmSciTech. 2007;8(4):E86. doi: 10.1208/pt0804086. PMID 18181547.
2. 2. Gomes H, Dubey A, Prabhu P. Development & evaluation of norfloxacin loaded maltodextrin based proniosomes. IRJP.2012;3(6):176-9.
3. 3. Ammar HO, Ghorab M, El-Nahhas SA, Higazy IM. Proniosomes as a carrier system for transdermal delivery of tenoxicam. Int J Pharm. 2011;405(1-2):142-52. doi: 10.1016/j.ijpharm.2010.11.003, PMID 21129461.
4. 4. Keleb E, Sharma K.R, Mosa E. Aim of the study based on proniosomes International Journal of Advances in Pharmaceutical Sciences. 2010; 1(2): 201-211.
5. 5. Ankur G, Sunil K, Balamurugan M, Mamta. Design & development of a proniosomal transdermal drug delivery system for captopril. TJPR. 2007;6(2):687-93.